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Background: The chemokine receptor, CC-chemokine receptor 3 (CCR3), and its major ligands, eotaxin,
RANTES, and MCP-4, are involved in eosinophil chemotaxis. It is thought that CCR3 plays an important
role in the recruitment and activation of eosinophils in nasal polyposis. We examined nasal polyp
extract-induced eosinophil chemotaxis and the effect of a CCR3 antagonist using EZ-TAXIScan, a novel
real-time chemotaxis assay device.
Methods: Nasal polyps were obtained from chronic rhinosinusitis (CRS) patients during surgery. The
polyps were homogenized and eotaxin levels in the extracts were measured. Eosinophils were puriﬁed
from human peripheral blood by the CD16 negative selection method. Nasal polyp extract-induced
eosinophil chemotaxis, with or without CCR3 antagonist, was assessed by EZ-TAXIScan.
Results: There was a signiﬁcant positive correlation between the eosinophil counts in nasal polyp and
eotaxin levels in the nasal polyp extracts. Using EZ-TAXIScan, eosinophil chemotactic responses were
observed following stimulation with nasal polyp extracts. There was a signiﬁcant positive correlation
between the chemotactic index toward the nasal polyp extracts and their eotaxin levels. Nasal polyp
extract-induced chemotaxis was completely inhibited by CCR3 antagonist but not by chemoattractant
receptor-homologous molecule expressed on Th2 cells (CRTH2) antagonist which inhibited PGD2-
induced eosinophil chemotaxis.
Conclusions: The CCR3 pathway may play an important role in the pathogenesis of eosinophil recruit-
ment in nasal polyps through selective eosinophil chemotaxis.
Copyright © 2016, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Nasal polyps occur more commonly in asthmatic patients, and
there are greater densities of activated eosinophils in nasal polyps
from asthmatic patients compared to non-asthmatics.1e3 Eosino-
phils play an important role in the pathogenesis of allergic airway
disease by secreting a wide variety of cationic proteins, lipid me-
diators, and cytokines/chemokines that mediate terminal effector
functions and the innate immune response.4 CC-chemokine re-
ceptor 3 (CCR3) belongs to a family of seven transmembrane-
spanning G protein-coupled receptors and binds three eotaxin
family proteins, eotaxin-1/CCL11, eotaxin-2/CCL24 and eotaxin-3/
CCL26, that are potent chemoattractants for eosinophils.5e7 Thelaryngology-Head and Neck
dicine, 1-1-1 Hondo, Akita
a).
ety of Allergology.
rgology. Production and hosting by Elseeotaxin concentrations of nasal polyp extracts are signiﬁcantly
increased in eosinophilic chronic rhinosinusitis (CRS) patients
compared to the non-eosinophilic CRS group.8,9 CCR3 plays an
essential role in eosinophil recruitment to the skin and the lung and
in the development of airway hyperresponsiveness in a CCR3-
deﬁcient mouse model.10 Because CCR3 expression is associated
with Th2 lymphocytes, eosinophils, and mast cells, CCR3 may be
central to the induction of the inﬂammation associated with
allergic disease.11,12 However, the role of CCR3 in eosinophil
recruitment in nasal polyps is not clear. To address this issue, we
employed a nasal polyp extract-induced eosinophil chemotaxis
assay with a novel real-time chemotaxis assay device, EZ-TAXIScan,
which can monitor and record horizontal cell migration.13 We
found that nasal polyp extract-induced eosinophil chemotaxis was
correlated with the eotaxin levels of nasal polyps, and addition of a
CCR3 antagonist completely inhibited chemotaxis. On the other
hand chemoattractant receptor-homologous molecule expressed
on Th2 cells (CRTH2) antagonist which inhibited PGD2-induced
eosinophil chemotaxis did not inhibit nasal polyp extract-inducedvier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
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pathway may play an important role in the pathogenesis of
eosinophil recruitment in nasal polyps through selective eosinophil
chemotaxis, raising the possibility that CCR3 antagonists may be
effective for the treatment of eosinophilic nasal polyps.Methods
Tissue collection
Nasal polyps were obtained from 12 patients with CRS (ﬁve
male and seven female) during endoscopic sinus surgery. There
were six asthmatic and six non-asthmatic patients. Systemic cor-
ticosteroids were discontinued at least one month prior to surgery.
The nasal polyp samples were divided in half, and one specimen
was immediately snap-frozen in liquid nitrogen and stored
at 80 C until processed. The other was ﬁxed in a 10% neutral
formaldehyde solution and embedded in parafﬁn. Counting of the
number of eosinophils in the nasal polyps was performed at high
magniﬁcation (400). In each patient, 5 visual ﬁelds were
randomly selected and the mean eosinophil count per ﬁeld was
calculated. The study was approved by the ethics committee of
Akita University School of Medicine. Informed consent was ob-
tained from each patient before collecting samples.Eotaxin assay
Nasal polyp samples were homogenized in 500 ml of buffer
containing 1% NP-40, 150 mM NaCl, 50 mM Hepes, and centrifuged
at 13,000 rpm for 10 min. The concentration of eotaxin in the nasal
polyp extracts was measured by an ELISA kit (R & D Systems,
Minneapolis, USA), according to the manufacturer's instructions.Eosinophil preparation
Eosinophils were puriﬁed from normal donor blood by negative
selection, as previously described.14 Brieﬂy, eosinophils were iso-
lated by sedimentationwith 6% dextran saline solution followed by
centrifugation on 1.088 Percoll (Pharmacia, St. Louis, USA) density
gradients. The cells were further puriﬁed by negative selection
using anti-CD16 immunomagnetic beads and a MACS system
(Miltenyi Biotec, Bergisch Gladbach, Germany). Eosinophil purity of
>98% was routinely obtained as determined by microscopic
analyses.Chemotaxis assay
Eosinophil chemotactic responses were measured using the
real-time chemotaxis assay device, EZ-TAXIScan (Effector Cell
Institute, Tokyo, Japan). The EZ-TAXIScan chamber was assembled
with a 260 mmwide  4 mm thick silicon chip on a 2 mm untreated
glass base, as described by the manufacturer, and ﬁlled with RPMI
medium containing 1% FBS. Eosinophil suspension (1 ml containing
2  106 cells/ml) was injected into one side of the EZ-TAXIScan
chamber. Chemoattractant solution (1 ml eotaxin, PGD2 or nasal
polyp extract) was injected into the opposite side of the chamber to
initiate chemotaxis. Migration of eosinophils over the glass surface
was recorded with a CCD camera located beneath the glass every
minute for 60 min at 37 C. At the end of the assays, we calculated
the chemotactic index by dividing the number of eosinophils that
had migrated over the halfway line towards the chemoattractants
by the number of eosinophils remaining at baseline.CCR3 or CRTH2 antagonist TREATMENT
Eosinophils (2  106 cells/ml in RPMI medium containing 1%
FBS) were incubated for 30 min with or without CCR3 antagonist,
SB328437 (1000 nM) (R & D Systems, Minneapolis, USA) and
CRTH2 antagonist, CAY10471 (1000 nM) (Cayman Biochemical,
Michigan, USA).
Statistical analyses
Data are presented as mean ± SE. Comparisons of two groups of
data were performed using the Wilcoxon single rank test, and
simple regression analysis was performed. Signiﬁcance was
established at the p < 0.05 level.
Results
Eosiniphil count and eotaxin level in nasal polyp
There was a signiﬁcant positive correlation between the eosin-
ophil counts in nasal polyp and eotaxin levels in the nasal polyp
extracts (Fig. 1).
Eosinophil chemotaxis induced by eotaxin
Migration of human eosinophils from normal donor blood to-
ward a concentration gradient of eotaxin (1000 nM) was recorded
using EZ-TAXIScan. Images were recorded everyminute for 60min;
images at 0, 10, 20, 40, 60 min tracing the trajectory of eosinophil
chemotaxis are presented (Fig. 2). The chemotactic index with
1000 nM eotaxin was signiﬁcantly higher than that of the control
(Fig. 3).
Effect of CCR3 antagonist on eosinophil chemotaxis
We investigated the effect of the CCR3 antagonist, SB328437 or
CRTH2 antagonist, CAY10471 on eotaxin (1000 nM) or PGD2
(1000 nM)-induced eosinophil chemotaxis to establishwhether the
CCR3 antagonist directly modulated the eosinophil chemotactic
response. Dose-dependent inhibition of eotaxin-induced chemo-
taxis of eosinophils by CCR3 antagonist and inhibition of PGD2-
induced chemotaxis of eosinophils by CRTH2 antagonist were
observed. CCR3 antagonist did not inhibit PGD2 -induced chemo-
taxis of eosinophils (Fig. 4). Our results indicated that the CCR3
antagonist inhibited the eotaxin/CCR3 chemotactic response
directly.
Eosinophil chemotaxis induced by nasal polyp extracts
The numbers of eosinophils in nasal polyps were signiﬁcantly
higher in asthmatic patients than in non-asthmatic patients (data
not shown). Migration of human eosinophils toward nasal polyp
extracts was recorded and images at 0,10, 20, 40, 60min tracing the
trajectory of asthmatic patients' nasal polyp extract-induced
chemotaxis are presented (Fig. 5aed). Inhibition of nasal polyp
extract-induced chemotaxis of eosinophils by CCR3 antagonist was
observed (Fig. 5eeh). There was a signiﬁcant positive correlation
between the chemotactic index toward the nasal polyp extracts and
their eotaxin concentration (Fig. 6). In addition, CCR3 antagonist
(1000 nM) inhibited nasal polyp extract-induced eosinophil
chemotaxis completely. On the other hand CRTH2 antagonist
(1000 nM) did not inhibit nasal polyp extract-induced chemotaxis
of eosinophils (Fig. 7). These results indicated that the CCR3
pathway has an important role in eosinophil recruitment in nasal
polyps.
Fig. 1. There was a signiﬁcant positive correlation between the eosinophil counts in nasal polyp and eotaxin levels in the nasal polyp extracts.
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This study demonstrated that nasal polyp extract-induced
eosinophil chemotaxis is correlated with the eotaxin level of
nasal polyps, and chemotaxis was completely blocked by CCR3
antagonist. These ﬁndings suggest that the CCR3 pathway plays an
important role in the pathogenesis of eosinophilic nasal polyps, and
CCR3 antagonists may be effective for the treatment of this
condition.Fig. 2. Chemotaxis of human eosinophils from normal donor blood toward a concentration
EZ-TAXIScan. Images of eosinophil chemotaxis were recorded every minute for 60 min. Imag
are presented.Nasal polyps occur more commonly in asthmatic patients, and
asthma is associated with a higher rate of recurrence of nasal
polyps after endoscopic sinus surgery.2,15 Eosinophilic inﬂamma-
tion is the major histologic hallmark of both asthma and CRS.16 The
histopathologic characteristics of asthma, namely, an intense
eosinophilic inﬂammation, basement membrane thickening,
erosion of the epithelium and features of airway remodeling, are
also present in CRS. CCR3 is highly expressed not only on eosino-
phils12,17 but also on basophils, mast cells and highly activated Tgradient of eotaxin (1000 nM) was recorded using a real-time chemotaxis assay device,
es at 0, 10, 20, 40, 60 min (aee) and tracing the trajectory (f) of eosinophil chemotaxis
Fig. 3. The chemotactic index was calculated by dividing the number of cells that
migrated past the halfway line by the number of cells remaining at baseline. The
chemotactic index of eotaxin (1000 nM) was signiﬁcantly higher than that of the
control. *p < 0.05 vs control.
Fig. 4. Dose-dependent inhibition of eotaxin (1000 nM)-induced chemotaxis of eosinop
eosinophils by CRTH2 antagonist were observed. CCR3 antagonist did not inhibit PGD2 -ind
Fig. 5. Migration of human eosinophils toward a nasal polyp extract was recorded using EZ-
polyp extract-induced chemotaxis are presented (aed). Inhibition of nasal polyp extract-in
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the inﬁltration of eosinophils into the airways, but also the devel-
opment of allergen-induced subepithelial and peribronchial
ﬁbrosis in a mouse model of allergic asthma.20 However, there is no
appropriate in vitro model of eosinophilic accumulation in nasal
polyps, and the role of CCR3 in eosinophil accumulation in nasal
polyps is not clear. To measure eosinophilic chemotaxis in vitro, the
trans-well or Boyden chamber method has most commonly been
used. However, while this method can provide endpoint data,
temporal analysis of cellular migration is not assessed, and
comparatively large numbers of eosinophils are needed for this
experiment (50,000 to 100,000 cells). EZ-TAXIScan is a novel
technique in which microchannels formed between a silicon sub-
strate and a ﬂat glass plate are used to observe cell migration,
including cellular chemotaxis.13,21 Cells moving horizontally via
microchannels can be observed with a microscope, and the
morphological changes cells undergo during chemotaxis, as well as
the directions they travel, can be observed in real time using a small
sample of cells (as few as 100 cells). Furthermore, computer controlhils by CCR3 antagonist and inhibition of PGD2 (1000 nM) -induced chemotaxis of
uced chemotaxis of eosinophils. *p < 0.05 vs control.
TAXIScan. Images at 0, 20, 60 min and tracing the trajectory of asthmatic patients' nasal
duced chemotaxis of eosinophils by CCR3 antagonist was observed (eeh).
Fig. 6. There was a signiﬁcant positive correlation between the chemotactic index
toward the nasal polyp extracts and the eotaxin levels in nasal polyps. R ¼ 0.63,
p < 0.05.
Fig. 7. CCR3 antagonist inhibited polyp extract-induced chemotaxis of eosinophils
completely. On the other hand CRTH2 antagonist did not inhibit nasal polyp extract-
induced chemotaxis of eosinophils. *p < 0.05 vs CCR3 antagonist ().
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cordings of cell migration.
In this study, the PGD2-induced eosinophil chemotaxis index
was higher than eotaxin-induced chemotaxis according to EZ-
TAXIScan. The speed of eosinophil chemotaxis toward PGD2 was
also higher than towards eotaxin (data not shown). Nitta et al. re-
ported that using EZ-TAXIScan, rapid eosinophil chemotactic re-
sponses were observed by stimulation with PGD2 and fMLP
compared to RANTES, although the migration lifetime of eosino-
phils was longer when they were stimulated with RANTES.21 The
mechanisms underlying the differences in response to chemo-
attractants was not clear. RANTES and eotaxin augment the func-
tional adherence of eosinophils.22,23 The establishment of a
gradient of the molecules (RANTES: M.W. 8720, PGD2: M.W. 352),
or the induced functional adherence of eosinophils by chemo-
attractant may affect the eosinophil chemotactic response. There is
a discrepancy in eotaxin levels between in polyp extract-induced
chemotaxis assay and eotaxin-induced chemotaxis assay. It was
reported that the levels of MCP-4, eotaxin, eotaxin-2 and eotaxin-3
in nasal polyp tissue were increased compared with sinonasal tis-
sue from control subjects.24 Not only eotaxin but also thesechemokinesmay play an important role in the eosinophil migration
in the nasal polyp through CCR3 pathway in eosinophils. PGD2
regulates various immunological responses via two distinct PGD2
receptors, prostaglandin D receptor (DP), and CRTH2 on eosinophils
and induces the migration of eosinophils through CRTH2.25 In this
study, eotaxin-induced chemotaxis was completely inhibited by
the CCR3 antagonist, while CRTH2 antagonist did not inhibit
eotaxin-induced chemotaxis. These results suggest that the CCR3
antagonist may inhibit the CCR3 pathway directly. Moreover, nasal
polyp extract-induced chemotaxis of eosinophils was completely
inhibited by CCR3 antagonist but not by CRTH2 antagonist. Taken
together, our data indicate the CCR3 pathway may play an impor-
tant role in the pathogenesis of eosinophilic nasal polyps through a
selective effect on eosinophil chemotaxis. Importantly, the quan-
titative methods described in the study could be useful for drug
screening to identify more effective options for the treatment of
nasal polyps.
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